Welcome to LookChem.com Sign In|Join Free
  • or
tert-butyl[(2S)-oxiran-2-ylmethoxy]diphenylsilane is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

106731-74-2

Post Buying Request

106731-74-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

106731-74-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 106731-74-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,7,3 and 1 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 106731-74:
(8*1)+(7*0)+(6*6)+(5*7)+(4*3)+(3*1)+(2*7)+(1*4)=112
112 % 10 = 2
So 106731-74-2 is a valid CAS Registry Number.

106731-74-2Relevant academic research and scientific papers

Stereoselective total synthesis and stereochemistry confirmation of photo-mycolactones

Li, Xiaoyong,Babu, Vaddela Sudheer,Kishi, Yoshito

, p. 3220 - 3224 (2015)

With use of the LiTMP-induced Hodgson cyclopropanation of an epoxide-olefin to a bicyclo[3.1.0]hexanol as the key step, a stereoselective total synthesis of photo-mycolactones was achieved. Each of the four diastereomeric epoxide-olefins, selectively prep

CD73 INHIBITORS

-

Page/Page column 42, (2019/09/18)

The present invention provides 5-[5]-[2-cycloa Ikyl ]-6-pyridazin-3-yl ]- IH-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer. (Formula (I))

COMPOUNDS AND METHODS FOR THE TREATMENT OF PARASITIC DISEASES

-

Page/Page column 81; 82, (2018/10/19)

Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods

Synthesis of Vicinal Dichlorides via Activation of Aliphatic Terminal Epoxides with Triphosgene and Pyridine

Cleveland, Alexander H.,Fronczek, Frank R.,Kartika, Rendy

, p. 3367 - 3377 (2018/03/26)

Herein we report a novel synthetic reaction to convert unactivated terminal aliphatic epoxide to alkyl vicinal dichloride based on triphosgene-pyridine activation. Our methodology is operationally simple and readily tolerated by a broad of scope of substrates as well as protecting groups. Furthermore, these mild conditions generally yield clean reaction mixtures that are free of byproducts upon aqueous workup.

Design, synthesis, and cytotoxicity of stabilized mycolactone analogs

Babu, Vaddela Sudheer,Zhou, Ya,Kishi, Yoshito

supporting information, p. 1274 - 1277 (2017/06/21)

On exposure to visible light, mycolactone A/B, the causative toxin of Buruli ulcer, rearranges to a mixture of four photo-mycolactones apparently via a rare photochemically-induced [4πs?+?2πa] cycloaddition. In

Antimalarial diterpenoid dimers of a new carbon skeleton from Aphanamixis grandifolia

Zhang, Hua,Liu, Jia,Gan, Li-She,Dalal, Seema,Cassera, Maria B.,Yue, Jian-Min

supporting information, p. 957 - 962 (2016/01/15)

Chemical investigation into the minor constituents of Aphanamixis grandifolia yielded three new diterpenoid dimers, aphadilactones E-G (1-3) featuring a new carbon skeleton. Their structures and absolute configurations were fully established by comprehensive spectroscopic data analysis and ECD calculation. Discovery of another two new dimers (4 and 5) suggested the structure of recently reported aphanamene A to be re-investigated. Compounds 1-5 showed moderate antimalarial activities with low micromolar IC50 values.

ARYL FUSED LACTAMS AS EZH2 MODULATORS

-

Page/Page column 98; 99, (2016/04/19)

This invention relates to compounds of Formula (I) in which R1, R2, R3, R4, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Total Synthesis, Stereochemical Revision, and Biological Reassessment of MandelalideA: Chemical Mimicry of Intrafamily Relationships

Willwacher, Jens,Heggen, Berit,Wirtz, Conny,Thiel, Walter,Fürstner, Alois

supporting information, p. 10416 - 10430 (2015/07/07)

MandelalideA and three congeners had recently been isolated as the supposedly highly cytotoxic principles of an ascidian collected off the South African coastline. Since these compounds are hardly available from the natural source, a concise synthesis rou

Synthetic studies on polymaxenolides: Model studies for constructing dihydropyran portion and synthesis of lower portion

Matsuda, Yutaka,Kato, Masaya,Kawaguchi, Tomonori,Koyama, Takayuki,Saikawa, Yoko,Nakata, Masaya

, p. 1154 - 1168 (2014/02/14)

With a goal of the total synthesis of polymaxenolide, the first hybrid marine natural product, the model studies for constructing the dihydropyran portion based on the originally proposed biosynthesis (C-C bond formation followed by dehydrative cyclization) and the synthesis of the lower portion (the C1-C3, C7-C17 portion) based on an iodide-induced Morita-Baylis-Hillman type reaction (a three-component assembly) followed by Suzuki-Miyaura cross-coupling are described.

ARYL AND HETEROARYL FUSED LACTAMS

-

Paragraph 0838; 0847; 0848, (2014/07/08)

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 106731-74-2